Companies › Boston Scientific
1 active drug program in 1 registered trial: 1 Phase 4; Cardiovascular.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| EkoSonicTM Endovascular System with ultrasound-facilitated thrombolysis Ultrasound-facilitated catheter-directed thrombolytic delivery | – | Phase 4 | Pulmonary Embolism | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT04790370 | EkoSonicTM Endovascular System with ultrasound-facilitated thrombolysis | Phase 4 | Pulmonary Embolism | Cardiovascular | Jul 2025 |
Cash of $609m on 2026-09-30; operating cash flow positive
Press releases filed as 8-K in the last year:
Held by 10 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
No annotated target.
–
Theravance Biopharma Inhibikase Therapeutics Kiniksa Pharmaceuticals International CeleCor Therapeutics MedTrace Pharma
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.